Skip to content

Safety of Low PEEP Maneuvers During ARDS Management

Safety of Low PEEP Maneuvers During ARDS Management

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05922969
Acronym
DEBAS
Enrollment
50
Registered
2023-06-28
Start date
2022-05-28
Completion date
2024-11-30
Last updated
2024-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome, Positive End Expiratory Pressure

Keywords

Acute Respiratory distress syndrome, Positive end expiratory pressure

Brief summary

Acute Respiratory distress syndrome (ARDS) is a severe condition in which protective ventilation is a critical point in its management. Positive end expiratory pressure (PEEP) setting can be challenging for clinicians and high PEEP has been associated with better outcome in moderate and severe ARDS. Recently, recruitment to inflation ratio and airway closure have been investigated in order to help PEEP adjustment. However, ventilatory maneuvers are performed with a low level of PEEP and therefore expose to derecruitment and oxygen desaturation. So far, the risk of oxygen desaturation has not been investigated and risk factors are unknown. The aim of this study is to evaluate the prevalence of oxygen desaturation during ventilatory maneuvers at low level of PEEP in patients with moderate or severe ARDS

Interventions

None listed

Sponsors

Centre Hospitalier VALENCIENNES
CollaboratorOTHER
Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age : \> 18 yo * inclusion criteria: ARDS, Mechanical ventilation, low PEEP maneuvers

Exclusion criteria

* refusal to participate

Design outcomes

Primary

MeasureTime frame
prevalence of oxygen desaturation24 months

Countries

France

Contacts

Primary ContactYoann Zerbib, MD
Zerbib.yoann@chu-amiens.fr03 22 08 77 23

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026